Information Provided By:
Fly News Breaks for July 7, 2016
TECH
Jul 7, 2016 | 08:49 EDT
Baird analyst Catherine Ramsey raised her price target for Bio-Techne to $115 from $108 after the company announced plans to acquire Advanced Cell Diagnostics for $250M in cash, plus $75M contingent consideration. The analyst believes Advanced Cell Diagnostics will be a "nice addition" to Bio-Techne's portfolio, with the deal expected to be completed on or about August 1. Baird has an Outperform rating on Bio-Techne's shares.
News For TECH From the Last 2 Days
TECH
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.